Marginal note:Definitions

1. (1) The following definitions apply in these Regulations.

“CGSB”

« ONGC »

“CGSB” means the Canadian General Standards Board.

“char length”

« longeur carbonisée »

“char length” means the maximum extent of the damaged length of a material that has been subjected to the test conditions set out in these Regulations.

“loose-fitting sleepwear”

« vêtement de nuit ample »

“loose-fitting sleepwear” means children’s nightgowns, nightshirts, dressing gowns, bathrobes, housecoats, robes, pyjamas and baby-doll pyjamas in sizes up to and including 14X, other than sleepwear designed for infants weighing up to 7 kg, sleepwear designed for use in a hospital or polo pyjamas.

“OECD”

« OCDE »

“OECD” means the Organization for Economic Cooperation and Development.

“tight-fitting sleepwear”

« vêtement de nuit ajusté »

“tight-fitting sleepwear” means any children’s sleepwear in sizes up to and including 14X other than loose-fitting sleepwear. It includes

• (a) sleepwear designed for infants weighing up to 7 kg;

• (b) sleepwear designed for use in a hospital;

• (c) polo pyjamas; and

• (d) sleepers.

Marginal note:Scope

2. These Regulations apply to the importation, advertising and sale of loose-fitting sleepwear and tight-fitting sleepwear.

Marginal note:Tight-fitting sleepwear

3. Tight-fitting sleepwear when tested in accordance with CGSB standard CAN/CGSB 4.2 No. 27.5 entitled Textile Test Methods – Flame Resistance – 45° Angle Test – One-Second Flame Impingement, as amended from time to time, must have a time of flame spread of more than seven seconds.

Marginal note:Loose-fitting sleepwear — Flame resistance test

• 4. (1) Loose-fitting sleepwear, when tested in accordance with the procedures set out in Schedule 1, must have

  • (a) an average char length for five specimens that does not exceed 178 mm; and

  • (b) not more than one individual specimen with a char length equal to the full length of the specimen.

• Marginal note:Loose-fitting sleepwear — other tests

  (2) Loose-fitting sleepwear that is treated with a flame retardant, any component that is extracted or broken down from such treated sleepwear, and any flame retardant that is used to treat the sleepwear must not cause any of the following consequences:

  • (a) acute lethality as a result of oral exposure to a dose of 500 mg/kg body weight or less or as a result of dermal exposure to a dose of 1000 mg/kg body weight or less when tested for acute oral toxicity or acute dermal toxicity in accordance with section 1 or 2, respectively, of Schedule 2;

  • (b) an effect graded at a mean greater than 1 for erythema formation or for edema formation measured at any specified time when tested for dermal irritation in accordance with section 3 of Schedule 2;

  • (c) when tested for dermal sensitisation in accordance with section 4 of Schedule 2, a response in greater than 15% of the test animals when using the Draize Test or the Buehler Test or in greater than 30% of the test animals when using one of the five other tests, in which an adjuvant is incorporated, that are specified in the OECD Test Guideline No. 406 that is referred to in that section;

  • (d) gene mutation or chromosomal aberration when tested for mutagenicity in accordance with section 5 of Schedule 2; or

  • (e) tumors when tested for tumorigenicity in accordance with section 6 of Schedule 2.